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effective as enoxaparin and cost-saving for the prevention of venous thromboembo-
lism after total knee replacement under the Brazilian public health care system 
perspective.
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ACUTE ISCHEMIC STROKE UNDER THE BRAZILIAN PUBLIC HEALTH 
CARE SYSTEM PERSPECTIVE
Teich V1, Passos RBF1, Vianna D2
1MedInsight, Rio de Janeiro, Brazil, 2University of Rio de Janeiro, Rio de Janeiro, Brazil
OBJECTIVES: To perform a cost-effectiveness analysis of thrombolysis with alteplase 
within 3 hours after acute ischemic stroke versus conservative treatment under the 
Brazilian public health care system perspective. METHODS: A Markov model was 
developed simulating acute stroke treatment with conservative treatment or alteplase. 
Three-monthly cycles were considered, during which, patients might transit between 
ﬁve post-stroke disability states, based on the modiﬁed Rankin Scale. The probability 
of presenting intracerebral hemorrhage after alteplase treatment and transition prob-
abilities in the ﬁrst year were obtained from NINDS trial. For subsequent years, 1-year 
cycles were considered, to account for patients’ mortality. The outcomes were 
expressed as life years gained (LYG). Both direct costs and indirect costs were con-
sidered in the analysis. Costs and outcomes were discounted at 5% per year. Results 
were segmented by gender and calculated for different time horizons, ranging from 1 
to 30 years. Unit costs for drugs were obtained from the Brazilian Health Prices 
Database, hospitalization and procedure costs were extracted from the National 
Database of Hospital Costs (SIH/DATASUS). RESULTS: In one year, incremental 
LYG were 0.0324 for both genders, with incremental costs of BRL608 for men and 
BRL363 for women. The incremental cost-effectiveness ratio in 1 year was BRL18,765/
LYG (US$13,404) for men and BRL11,204/LYG (US$8,003) for women. After the 
second year, alteplase became cost-saving. The shorter length of hospitalization and 
reductions in rehabilitation needs and productivity losses overweighed incremental 
drug costs. (2005 PPP 1USD  1.4BRL). CONCLUSIONS: Thrombolytic therapy with 
alteplase in the ﬁrst three hours after stroke changes the natural history of disease, 
reducing both direct and indirect costs. In the long term, there are large scale resource 
savings for the Brazilian public health care system.
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COST EFFECTIVENESS ANALYSIS OF ROSUVASTATIN 10 MG VS. 
ATORVASTATIN 20 MG FOR THE TREATMENT OF 
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OBJECTIVES: Make a comparison between Atorvastatin 20 mg and Rosuvastatin 
10 mg in the treatment of hypercholesterolemia in the Mexican public institutions. 
METHODS: We performed a cost-effectiveness analysis comparing Atorvastatin 
20 mg with Rosuvastatin 10 mg. The effectiveness outputs were percentage of Low 
Density Lipoprotein Cholesterol (LDL-C) reduction and percentage of patients that 
achieve ATPIII goals after one-year treatment. Effectiveness variables were based on 
the results of the STELLAR study and costs were obtained from a local wholesaler 
(NADRO) prices list. We used the National Health and Nutrition Survey (ENSANUT) 
of 2006 to gather general prevalence information. Results are reported in U.S. dollars 
with and exchange rate of 15 MXN per dollar. RESULTS: Annual treatment cost of 
Rosuvastatin 10 mg was $558.04 and Atorvastatin 20 mg was $1,169.24. We found 
an annual difference of $611.2 per patient. This means that if all the population with 
hypercholesterolemia reported by the ENSANUT 2006 were treated with Rosuvastatin 
instead of Atorvastatin a total of $10,613 million would be saved by the payer. The 
cost of one patient achieving the ATPIII goal with Rosuvastatin was $680.13 while 
with Atorvastatin the cost was $1,565.88. Cost of 1% reduction of LDL-C was $12.18 
for Rosuvastatin and $27.45 for Atorvastatin. CONCLUSIONS: Rosuvastatin 10 mg 
is more effective in both measurements (achieving ATPIII goals and reducing LDL-C) 
and is less costly than Atorvastatin 20 mg, therefore dominates over the compared 
treatment. The use of Rosuvastatin 10 mg instead of Atorvastatin 20 mg translates in 
huge saving to the public institutions in Mexico.
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OBJECTIVOS: En México se estima que existen q100 mil casos nuevos detectados/año 
de trombosis venosa profunda (TVP) que originan 500,000 días/hospitalización y 
que la tromboembolia pulmonar (TEP) tiene una mortalidad intra-hospitalaria cercana 
al 47%. El objetivo de este trabajo fue identiﬁcar la alternativa más costo-efectiva 
para la proﬁlaxis de la ETV desde la perspectiva del IMSS. METODOLOGÍAS: 
Evaluación económica completa. Se construyó un árbol de decisiones comparando los 
resultados en salud (estimados mediante meta-análisis) de tres alternativas anticoagu-
lantes actualmente disponibles en el IMSS (heparina más warfarina, enoxaparina y 
fondaparinux) y los costos de la atención en el contexto de esa institución, versus los 
resultados y costos alcanzados por el uso del innovador dabigatrán. RESULTADOS: 
El esquema proﬁláctico basado en heparina no fraccionada más warfarina fue tomado 
como comparador común por ser el de menor precio y uno de los más empleados. 
Dabigatrán resultó ser la alternativa dominante en la proﬁlaxis de TVP con una ICER 
de -$62.64 (IC95% $61.71–$63.57) por caso evitado. Lo mismo sucedió en el caso 
de TEP donde la ICER fue de -$1,002.28 (IC 95% $987.39–$1017.17) por 
caso evitado. Un análisis de sensibilidad multivariado conﬁrmó estos resultados. 
CONCLUSIONES: Debido a que dabigatrán es un medicamento oral, de dosis ﬁja y 
de efecto predecible, facilita un mayor apego al esquema proﬁláctico en comparación 
con el esquema comparador y con ello disminuye el riesgo de TVP o de TEP. Dabig-
atrán es la opción más eﬁciente para prevenir estos eventos en el contexto del IMSS.
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OBJETIVOS: Este estudo visa avaliar os estudos de custo–efetividade da Rosuvasta-
tina versus a Atorvastatina no tratamento da hipercolesterolemia e avaliar a necessi-
dade de incorporá-la no Brasil, pela listagem de Medicamentos Especiais para 
dislipidemias do Sistema Único de Saúde (SUS). MÉTODOS: Foi realizada uma busca 
nas bases de dados PubMed, Medline, Google Acadêmico, Bireme, Biblioteca do 
Centro Cochrane do Brasil, The Cochrane Library Clinical Evidence e Biblioteca do 
Conhecimento, de todos os estudos de custo–efetividade e Revisões Sistemáticas que 
avaliam a Rosuvastatina versus a Atorvastatina. Foram analisadas as populações 
envolvidas, a perspectiva do estudo, intervalo temporal, dados do estudo, medidas de 
efetividade, custos avaliados, modelagem econômico, taxas de desconto, análise de 
sensibilidade, limitações, conﬂitos de interesse, resultados principais. RESULTADOS: 
A Rosuvastatina, em diferentes dosagens, demonstrou em todos os estudos analisados 
ser mais custo–efetiva entre todas as estatinas comparadas, inclusive quando analisada 
com a Atorvastatina em relação à segurança, eﬁcácia e custo–efetividade. Em pacientes 
de alto-risco com hipercolesterolemia, a Rosuvastatina foi o medicamento que reduziu 
mais signiﬁcativamente os níveis de LDL e os custos de tratamento foram menores, 
diminuiu a quantidade de pacientes que realizaram novas consultas médicas necessi-
tando aumentar a dose do medicamento, bem como o número de exames laboratoriais. 
CONCLUSÕES: A rosuvastatina tem poucos estudos que a avaliem frente a outras 
estatinas. É necessário que estudos no Brasil sejam realizados, sem conﬂitos de inter-
esse, para avaliar mais profundamente a rosuvastatina. A rosuvastatina é efetiva, tem 
preços de venda mais baixos que a Atorvastatina podendo ser custo–efetivo incorporá-
la na Lista dos Medicamentos Especiais do SUS, para pacientes com hipercolesterol-
emia e risco alto para doenças cardiovasculares. Para pacientes com baixo risco e que 
necessitar menor redução de LDL-C poderão ser utilizadas estatinas que tenham 
menor custo e menor efetividade.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To evaluate compliance with drug treatment in patients with metabolic 
syndrome as well as weight loss and physical activity practicing during a 12-month 
follow-up. METHODS: This was a longitudinal study, with a 12-month follow-up, 
involving 45 patients with metabolic syndrome according to IDF criteria, who were 
being treated in a Health-Medical School Center under the Brazilian Healthcare 
System. Patients were evaluated every three months. The Measure Treatment Adher-
ence, a variation of the Morisky-Green Test, in a 1 to 6 scale, was used to assess 
patient behavior patterns associated with the use of medicines. Parameters to evaluate 
compliance with non-drug treatment were: to achieve a 10% weight reduction in total 
body weight and to perform a minimum of 30 minutes of physical activity at least 
three times a week. RESULTS: Average levels of compliance in each measurement 
were: 5.49 o 0.44 (at inclusion); 5.68 o 0.57 (3-month follow-up); 5.87 o 0.28 (6-
month follow-up); 5.79 o 0.44 (9-month follow-up); 5.72 o 0.46 (12-month follow-
up). At the end of 12-month period, 4 patient achieved weight reduction goal. Average 
% weight variations in relation to the established goal were: k10.2% o 2.9 (3-month 
follow-up); k10.0% o 6.5 (6-month follow-up); k10.1% o 7.2 (9-month follow-up); 
k10.5% o 7.5 (12-month follow-up). Patients who practiced no physical activity were: 
62% (at inclusion); 60% (3-month follow-up); 64% (6-month follow-up); 69% (9-
month follow-up); 69% (12-month follow-up). The majority of patients who practiced 
physical activities spent more than 30 minutes per exercise session. CONCLUSIONS: 
Patients involved in this study exhibited a high level of compliance with drug treat-
ment. More research is needed to conﬁrm if this result is characteristic of patients 
treated in a Health-Medical School Center. Although regular practice of physical 
activity and weight loss are associated with signiﬁcant clinical improvements, both 
these issues need to be better addressed.
